IMPACT
No longer recruiting
Summary This study aims to evaluate the effect of IMCY-0098 on the immune signature (treatment-specific biomarkers), and the effect of the study drug upon the preservation of beta-cell function in adult patients with Type 1 Diabetes. Further safety data will also be collected.Research study for people with Type 1 Diabetes: EXALT
No longer recruiting
Summary
The main purpose of this study is to assess the safety of three different doses of an investigational drug in patients who have been recently diagnosed with type 1 diabetes. The investigational drug is a “therapeutic vaccine” and affects the body’s immune system response to a medical condition or disease. It is designed to stop the immune system from attacking cells that produce insulin, which may help insulin production in patients with recently diagnosed type 1 diabetes.
ADDRESS C-Peptide
No longer recruiting
Summary Observational study to find out how much insulin people with type 1 diabetes can make themselves within the first year of having diagnosis and how C-peptide varies with time since diagnosis in children and adults.EXTOD Education
No longer recruiting
Summary
We (the EXTOD Education Team) want to find the best way to support adults with Type 1 diabetes to manage their glucose during and after exercise, so that they can exercise safely. Our research study, the ‘EXTOD education’ study, has developed a NEW intervention (an education programme) to assist in achieving this goal.
We are inviting people with Type 1 diabetes to participate in a Pilot Randomised Controlled Trial, involving 8 visits over an 8 month period, to test the new education programme.
The Effect of Abatacept on the Immune System in Type 1 Diabetes
No longer recruiting Summary This study aims to gain a better understanding of the immune processes that lead to the destruction of insulin producing beta cells. Participants will be given the drug Abatacept for 6 months, in addition to their regular diabetes medication. They will have blood tests before, during and after treatment so that their immune cells can be analysed.Exploration of the peripheral immune system in subjects with New Onset T1 Diabetes (NOT1D)
No longer recruiting
Summary This study aims to gain a better understanding of the processes that may lead to the immune system’s destruction of insulin producing beta cells, which help to control blood sugar levels. This study involves taking a biopsy (a sample of tissue taken from the body in order to examine it more closely) from a lymph node found in the groin area.The effect of anti-IL-21 and liraglutide in newly diagnosed type 1 diabetes
No longer recruiting
Summary This study will investigate if a new drug called NNC01140006 (Anti-IL-21) when given together with another drug marketed for type 2 diabetes called liraglutide (Victoza®) can preserve the beta cells in subjects diagnosed with type 1 diabetes.MultiPepT1De
No longer recruiting
Summary
Trial of a potential vaccine for type 1 diabetes for adults aged 18-45 years, within 4 years of diagnosis.
www.multipeptide.co.uk
Aim
To investigate the possibility of slowing the progression of type 1 diabetes using a “vaccine”. The vaccine is made from fragments of the protein molecules found in the beta cells of the pancreas, called peptides. The aim is to re-train the immune system so that it stops recognising beta cells as a target to attack. The current study is testing the safety of the vaccine as well as its effects on the immune system.
Who is running this study?
This study is academically led and is being run by Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. The Chief Investigator is Dr Jake Powrie.
It is funded by a grant from UCB Pharma.
